Molecular Partners AG lost $2.08 per diluted share in fiscal year 2025. The change from the prior fiscal year is not meaningful, because that figure was zero or negative. The table below carries 7 fiscal years, from 2019 to 2025, and the quarters Molecular Partners AG has filed alongside them.
FY2025 annual
EPS (Diluted)-$2.08
YoYn/m
5Y CAGRn/m
Source SEC Filings (20-F/6-K)Latest period FY2025, ended Dec 31, 2025ReportedCurrency USD
Annual figures, oldest first. Point at a bar to read its period.
MOLN EPS (Diluted) by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.
Molecular Partners AG lost $2.08 per diluted share in fiscal year 2025.
Molecular Partners AG (MOLN) reported a loss of $1.75 per diluted share in fiscal year 2024 and a loss of $2.08 per diluted share in fiscal year 2025. A growth rate is not meaningful here, because the earlier figure was zero or negative.
Across the 7 fiscal years this page covers, Molecular Partners AG (MOLN) diluted earnings per share went from -$1.75 in fiscal year 2019 to -$2.08 in fiscal year 2025.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Molecular Partners AG (MOLN) reported on that line in every period on record.
